Skip to main content
Premium Trial:

Request an Annual Quote

Tokai, JHU Ink CDx Deal for Castration-Resistant Prostate Cancer Rx Development

NEW YORK (GenomeWeb) – Tokai Pharmaceuticals said today it is working with Johns Hopkins University to develop a companion diagnostic for its investigational, castration-resistant prostate cancer (CRPC) drug galeterone.

Under its agreement, Cambridge, Mass.-based Tokai has garnered an exclusive, worldwide license from JHU for "patent applications and know-how" covering a test used to assess the AR-V7 status of prostate cancer patients.

According to Tokai CEO Jodie Morrison, the company will use the companion test in a 148-patient, Phase III ARMOR3-SV trial, slated to start in the first half of 2015. Tokai is developing galeterone for metastatic CRPC patients who express a truncated version of the androgen receptor, called AR-V7. Galeterone is designed to interrogate androgen receptor signaling, which drives prostate cancer.

Patients with truncated androgen receptors are missing the C-terminal end involved in ligand binding, and AR-V7 is the most frequently occurring splice variant that causes this terminal loss. A prospective JHU study, as well as retrospective analyses by MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, suggests that patients with C-terminal loss and AR-V7 are poor responders to existing metastatic CRPC drugs such as Janssen Biotech's Zytiga (abiraterone acetate) and Astellas' Xtandi (enzalutamide).

Preclinical data generated by Tokai on galeterone, as well as a Phase II trial involving the drug, suggests that it may benefit CRPC patients with AR-V7 and C-terminal loss.

Tokai said it has also finalized an agreement with Qiagen for the development of a non-invasive companion diagnostic for galeterone "utilizing an array of novel technologies."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.